(< 18 years old) Pompe Disease (PD) and 132 for adult onset PD. We then selected studies based on their strength of recommendation and quality of evidence. In August 2014, a new search identified 329 studies published between the years 2010 and 2014.
Strength of recommendation and quality of evidence: A. experimental studies or strong observational studies (randomized);B. experimental studies or other observational studies (case-control); C. Case reports (uncontrolled studies); D. expert opinion without critical evaluation, based on consensus, physiological studies or animal models.
PD Definition
Pompe disease (PD) (OMIM # 232300), also known as glycogen storage disease type II, is a rare lysosomal storage disease classified as an inborn error of metabolism 1 . It is caused by partial or complete deficiency in the activity of the acid alpha-glucosidase enzyme (GAA) (EC 3.2.1.20), which is essential for the degradation of lysosomal glycogen into glucose. This deficiency causes a progressive accumulation of glycogen in the cells of various tissues, manifesting in multisystem form, predominantly in the skeletal, cardiac and smooth muscle systems 1 . PD has been defined as a low/abnormal activity of the GAA enzyme in asymptomatic or symptomatic individuals and/or presence of two pathogenic mutations in the GAA gene 2 (B).
ePiDeMioloGy
The frequency of PD is quite variable (Table1). Recently, through a blind analysis of 100,000 samples obtained from neonatal screening through mass tandem spectrometry, Scott et al. 3 (B) identified, among other lysosomal diseases (Fabry and mucopolysaccharidosis type 1 -MPS I), an incidence of PD about 1/27,800 of the newborns.
On the other hand, a study conducted in 104 muscle biopsies from asymptomatic or oligosymptomatic ( fatigue, cramps, myalgia) patients, with increased serum CK, normal physical examination and no statin exposure, PD in juvenile and adults (PDJ-A) was identified in 3.8% of patients 4 (C). Werneck et al.
5
, in a particular study of symptomatic cases, reviewed 4,500 muscle biopsies performed over a period of 33 years in a reference center for neuromuscular diseases in Brazil and identified 19 cases of PD, 10 cases of early onset PD and 9 cases of PDJ-A (C).
PathoPhysiology
PD is an autosomal recessive disease caused by pathogenic mutations in both copies of the gene that encodes the enzyme GAA. Hundreds of mutations have been identified in the GAA gene (http://www.pompecenter.nl/).
PD severity and age of symptom onset are related to the level of residual activity of the GAA enzyme. Early onset infantile PD results from a complete deficiency of the enzyme (activity < 1%), while late onset PD (juvenile or adult) results from partial deficiency of GAA (1-30%). Onset may occur as early in childhood or as late as at the sixth decade of life 6, 7 (B). The cause of PD is the progressive accumulation of intralysosomal glycogen due to the inability of the cell to breakdown the lysosomal glycogen into glucose. As a result, lysosomal membranes rupture, causing leakage of hydrolytic material into the cytoplasm with impairment of the muscle contractile unit 1 . There is also saturation of autophagic pathways during the pathophysiological process 8 (C).
syMPtoMs anD siGns of jUvenile anD aDUlt PoMPe Disease (table2)
The clinical manifestations vary according to the patient' s age, the rate of disease progression and the extent of organ involvement, and may result in irreversible motor impairment 9,10 (B). The most common manifestation in adults is progressive muscle weakness simulating the muscular dystrophies. Most patients present weakness of the proximal and axial musculature, especially in the lower limbs 14, 15 (C). Weakness of the paraspinal muscles of the lower back, weak and protruding abdominal muscles, weakness of facial muscles and eyelid ptosis and tongue paralysis reinforce the clinical suspicion 11, 12, 13 . The presence of dysphonia and dysphagia reflects the disease's bulbar impairment 14 , and involvement of the auditory system has also been reported 15 .
GUiDeD Physical exaMination
The physical examination in PDJ-A should focus on the muscular and respiratory systems. 
Differential DiaGnosis
Early involvement of respiratory muscles anticipating muscle weakness may differentiate PDJ-A from other neuromuscular diseases 17 . Table 3 lists the diseases considered in the differential diagnosis of PDJ-A.
DiaGnostic laboratory MethoDs for jUvenile anD aDUlt PoMPe Disease
Dry blood spot on filter paper as a screening test for PD The introduction of the dry blood spot (DBS) test on filter paper into clinical practice provided a simple and reliable laboratory method for screening patients with suspicion of PD 26, 27 (Table 4 ). Whenever the suspicion of PD persists, the test should be repeated, and additional diagnostic methods should be employed ( Table 4) . As all screening tests, suspected cases require a confirmation by at least one diagnostic test 26, 27 (B, C). DBS pre-analytical problems may result in false-negative and/or false positive screening results
26
.
laboratory diagnosis for childhood and adult PD
Upon a positive DBS screening test for PD, additional diagnostic evidence should be obtained by measuring the amount of GAA activity in leukocytes or fibroblasts 26 and/or by conducting GAA genotyping in search of two pathogenic GAA mutations 2 (Table 4) . Whenever there is any doubt in the DBS test and clinical suspicion persists, patients with symptoms suggestive of PD should have their GAA activity measured once again by the same laboratory that performed the first analysis. If the patient is negative for the GAA enzyme assay in leukocytes and the possibility of PD persists, diagnosis should proceed with at least one of the following three options: a) DNA analysis searching for pathogenic mutations in the GAA gene 2 ; or b) Muscle biopsy evaluation, to assess the presence of abnormal accumulation of glycogen with vacuolar myopathy 5, 29 (B), although not specific for PD; or c) Fibroblast culture from skin biopsy to test for GAA activity 26 .
Genetic asPects of jUvenile anD aDUlt PoMPe Disease Patients -GenotyPe-PhenotyPe correlation anD criM statUs
The enzymatic deficiency in PD is caused by pathogenic mutations in both alleles of the GAA gene. Mutations can be similar (homozygote); or, different (compound heterozygote); however, both within the GAA gene. The most common mutation observed in PDJ-A patients, including Brazilians, is the intronic alteration c.-32-13 T > G (IVS1-13T > G), which is observed in more than two-thirds of the patients worldwide 7, 30 . The type and combination of these mutations will determine the amount of residual GAA activity in the cells 6, 7 . The combination of two severe mutations leads to a complete lack of GAA protein and, as a consequence, an extremely low residual GAA activity (< 1%); such genotype is associated with the severe early onset PD On the other hand, any other combination of mutations, being at least one of then considered a "milder" mutation, such as the classic c. -32-13 T > G, enzyme production will occur, even if abnormally, resulting in different levels of residual GAA activity of up to 30% of the normal value 6, 7 . Patients with at least one mild mutation constitute most cases of juvenile and late-onset PD and present a clinical phenotype with a slower progression 1, 7 . From an immunological standpoint, these patients are classified as CRIM positive
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, and generally, will probably not be prone either to severe adverse reactions to Enzyme Replacement Therapy (ERT) with the rhGAA enzyme or sustain high titers of antibodies 33 (B).
enzyMe rePlaceMent theraPy in Patients with chilDhooD anD aDUlt PoMPe Disease
Until recently, treatment for PD consisted only in palliative care. In a natural history study of 255 patients with DPJ-A, disease severity assessed by the need for a wheelchair or dependence on mechanical ventilation showed that progression to wheelchair use increased, on average, 13% each year in patients without ERT treatment 34 (B). In 2007, the commercial use of the rhGAA enzyme was approved for early onset PD patients; and, in 2010, for the late-onset PD presentation. In the 18-month clinical trial conducted with the rhGAA enzyme in the late-onset PD form, there was an increase in the six minute walk test as well as stabilization of their pulmonary function 35 (A). The goals of rhGAA enzyme therapy depend on the stage of disease progression 35, 36 (B), and include: • To slow down, stabilize or reverse disease progression;
• To reduce comorbidities and increase survival;
• To improve mobility, preserve motor function, delay the need for walking assistance, and promote motor gains; • To improve or maintain respiratory function, thus preventing the need for respiratory assistance; • To improve or preserve patient independence and quality of life. A systematic review 37 of the clinical and therapeutic outcomes of ERT with the rhGAA enzyme after one year of treatment in 251 patients with the PD-A presentation and 27 patients with juvenile PD yielded the following findings:
• six-minute walk test: 78% increased the distance covered, 8% maintained the same distance, and 4% decreased the distance; • Motor Performance: 10% improved, one bedridden patient was able to sit up, three patients in wheelchairs .
Screening Test -DBS -"dried blood spot" on filter paper to perform enzymatic activity analysis of acid α-glucosidase (GAA) were able to walk a few times a day, and three patients no longer required wheelchairs; • Forced Vital Capacity (FVC) (127 patients): 53% improved and 33% worsened; • Ventilatory support (58 patients): 70% improved.
The delay between the first symptoms of the disease, the definitive diagnosis of DPJ-A, and the beginning of ERT, have shown an inverse relationship with the therapeutic prognosis and clinical outcomes desired 38 .
Practical instructions for enzyme replacement therapy
Currently, there is only one commercially available product for ERT with the rhGAA enzyme for PD (Reg MS: 1.2543.0020.001-0.)
Regardless of the PD type, treatment with the rhGAA enzyme should be started at a reference hospital where it would be possible to intervene in the event of any adverse event related to the venous infusion 39 . It is also essential to inform the family about the goals of ERT, the treatment expectations based on the stage of the disease, and the guidelines for clinical follow-up and evaluation 28, 40 . Health professionals should address the difficulty of predicting the response to long-term ERT treatment and prioritize factors that could potentially influence treatment response, such as respiratory function and muscle involvement. The multidisciplinary team should be instructed regarding these issues. We recommend training the nursing and pharmacy staff on the handling of the drug prior to the first infusion, and provide specific guidance to physicians and the infusion center staff. One should always record the occurrence of any adverse event, whether or not they are associated with ERT. The dose of rhGAA enzyme for ERT should follow the manufacturer's recommendations. The current standard dose of Myozyme® is a minimum four-hour infusion of 20mg/kg every 15 days.
While adverse events in patients with PDJ-A are considered rare (see Genotype-Phenotype correlation) 39 , infusion-related reactions generally require medical intervention. These reactions are usually mild to moderate and respond positively to a reduction in infusion rate.
The most serious and rarely observed side effects of ERT with rhGAA are life-threatening anaphylactic reactions, serious allergic reactions and immune-mediated reactions. Such events are also rare in late-onset PD because patients are CRIM positive 32 . inclusion and exclusion criteria for enzyme replacement therapy (table 5) The heterogeneity of symptoms and signs present in PD patients (Table 2) , the intra-familial variability and different stages of PD have led to the characterization of different patient groups and created a clinical dilemma of when to put a patient on ERT with rhGAA. The groups currently are identified as newborns identified via newborn screening 8 ; asymptomatic patients with or without clinical signs of the disease 41 ; symptomatic PD patients 36 and patients with severe PD 9,10 ( Table 5 ). If the patient is confined to a wheelchair and using continuous invasive ventilation: ERT is recommended for 01 year, followed by evaluations to assess therapy effectiveness After 01 year of ERT, the multidisciplinary team will review the treatment case-by-case, especially for patients requiring continuous invasive ventilation ERT will be continued if there is stabilization or improvement of severe signs and symptoms ERT duration Annual reassessment to review the effectiveness of treatment Monitoring
Patients receiving enzyme replacement therapy should have IgG antibody levels monitored every 03 months for up to 02 years, and then annually (www.registrynxt.com)
ERT: enzyme replacement therapy.
In most cases of PDJ-A, the duration of rhGAA treatment is indefinite. Thus, the treatment goals, the timing of clinical evaluations, and quality of life studies (SF-36 -www.sf-36.org/), may support the multidisciplinary team in clinical management decisions 28, 40, 41 . It appears that major improvement of muscle strength and respiratory function with ERT is not common in patients with late-onset Pompe's disease 35 . The termination of ERT can be a very difficult task, and there is no consensus regarding this topic except on a case-by-case discussion. The involvement of family members in such decisions is very important 28, 40 (Table 5 ).
Monitoring and laboratory tests for enzyme replacement therapy
PD patients on ERT with the rhGAA enzyme will make seroconversion in 95% of cases becoming IgG positive 39 . However, exceptionally high titers of persistent antibodies may occur and this can activate the complement cascade and neutralize the rhGAA enzyme 32 . In these circumstances, there is a decline of the therapeutic response to ERT (walking, lung function, SF-36) and adverse events associated to ERT may be observed 32 (B). Currently, immune modulation and immune suppression protocols, in an attempt to reduce neutralizing antibodies against rhGAA, have been successfully applied in infantile onset PD patients with high sustained IgG antibodies 42 . Patients with PDJ-A are CRIM-positive and therefore are less likely to have such serious immunological reactions 32 . The concentrations of IgG and IgE antibodies, tryptase and complement activation studies need to be monitored based on the Doctor's Guide to Clinical Management of Pompe Disease.
Hypersensitivity to the drug should be considered an absolute contraindication to the use of ERT with rhGAA enzyme.
Pregnancy, lactation and enzyme replacement therapy
Since the introduction of ERT, a growing number of women with metabolic diseases have been able to reach reproductive life and become pregnant. Pregnant women with Gaucher, Fabry and (more recently) Pompe disease, are creating a new clinical challenge for obstetricians 43, 44 . Until 2014, two cases of pregnant women with PD receiving ERT have been published 44, 45 . Recently, Karabul et al. 46 collected information on 52 women with PD-A and 125 pregnancies through a retrospective self-administered questionnaire sent to Pompe associations in England and Germany, as well as neuromuscular disease centers in Germany. Pregnant women undergoing ERT not exhibited a reduction in mobility and muscle function, and many asymptomatic patients experienced their first PD symptoms during pregnancy 51 . Many pregnant women also used wheelchairs intermittently. A decrease in lung function, as measured by spirometry, was common to all pregnant women, including those undergoing ERT. Nonetheless, the reported experiences were highly favorable to the use of ERT during pregnancy, anesthesia, postpartum, newborn health, lactation and recovery of prepregnancy clinical status 46 . FDA classification/pregnancy category B (http://www.accessdata.fda.gov).
Pregnant women with neuromuscular diseases and vital capacity < 1l (normal reference = 4.5l) should be warned of the high risk of complications during pregnancy and childbirth. In case of maternal hypoxia with O 2 saturation under 85%, the rate of live births is only 12%. The recommendation for pregnant women with PD is a cesarean delivery under local instead of general anesthesia 47 .
MUltiDisciPlinary clinical MonitorinG
Due to the predominance of muscular signs and symptoms, PDJ-A is primarily a neuromuscular disease. Thus, the neurologist's role is crucial in coordinating the clinical decisions made by the professional health team 2, 28, 40 . The ICD-10 classification (E74.0) may not accurately describe the functional impairment and disability associated with PD, since these patients vary in their degree of functionality. The International Classification of Functioning, Disability and Health (ICF) 48 provides more meaningful information and data for clinical purposes (Table 6) .
A study of 210 adults with PD using the Quality of Life Scale (SF-36) survey 34 highlights the impact of the disease on patients' ability to work, perform household activities and move independently outside of their home. Progressive disability also increases the dependence of family members and other supportive care in the management of PD patients.
We recommend using disability scales (the Rotterdam study), visual analog scales for measuring pain, and the SF-36. active physical activity Recent evidence shows that people with carbohydrate processing disorders can benefit from light exercise 50 (C). People who are physically fit are better able to use alternative sources of fuel for energy. Excessive strain in PDJ-A can cause muscle injuries; therefore, all exercise programs should be supervised by a professional familiar with PD (Table 6) .
Therapeutic exercise should start lightly, be interspersed with rest periods, and follow a gradual increase in intensity until it reaches 60-75% of maximum effort in three to five days per week 50 (B). Strenuous or eccentric physical therapy exercises should be avoided, especially in proximal muscles, flexors and abductors of the lower limbs (Nascimento, Siqueira and Barone, personal observation, 2014).
Optimization of the biomechanical advantages of movement:
• Provide positioning and support to increase biomechanical advantage; • Save energy;
• Optimize the effects of gravity; • Consider positions that improve the muscle length-tension relationship • Minimize muscle contracture.
Prevention of secondary musculoskeletal deficits (table 7)
Secondary musculoskeletal impairments can be prevented by following the principles of biomechanics to counteract deforming forces. This is done by applying light pressure, stretching, practicing posture correction, performing orthotic interventions, and using seating and support systems 51 . Recent studies show that the mobilization and utilization of fat and carbohydrates in skeletal muscles during exercise are normal in PD. In fact, the reduction in exercise capacity results from muscle weakness and wasting and not from a reduction of muscle glycogenolysis, even with ERT therapy 51 (B).
Pulmonology
Respiratory failure is a major cause of mortality and morbidity in PDJ-A 10,11,17 (B). Approximately 60% of individuals with PDJ-A show a slight decrease in vital capacity (less than 80% of normal) and 30-40% show a moderate decrease (less than 60% of normal) 10,11 (C). Observational studies have shown average annual declines in FVC of 1.7% to 4.6% 11 (B). As PDJ-A progresses, muscles weaken and lung volume is reduced. Consequently, cough can become harmful, nutritional and gastrointestinal evaluation and treatment PD patients have difficulty swallowing and eating. Factors contributing to this difficulty include facial hypotonia, macroglossia, weakened tongue muscles, and impairment of oral movements. Patients have difficulty dealing with saliva and secretions usually accumulate on the vocal cords, which can also lead to respiratory complications. They experience fatigue of the jaw muscles as well as difficulty chewing and eating certain foods. For these reasons, patients with PD often consume low amounts of vitamins, minerals and energy, resulting in malnutrition and the compensatory use of muscle proteins, in addition to increased risk of microaspirations and aspiration pneumonia by vomiting or regurgitation. Also, nutritional problems arising from gastrointestinal muscle weakness may also be present, including dysphagia, gastroesophageal reflux, gastroparesis, and decreased bowel movements leading to constipation.
Patients should be assisted by a group of professionals that includes: a speech therapist, a stomal therapist, a psychologist, a dietitian and a nutrition specialist (preferably with experience in metabolic diseases) to ensure proper nutritional care. Diets and food consistency should be reassessed regularly.
For patients with PDJ-A, the main goal of the diet -other than adequate nutrition -is to control glycogen accumulation and the processing of amino acids. We recommend a high protein diet (20-25% of total energy intake from protein, 30-35% from carbohydrates and 35-40% from lipids), with special attention to vitamins and minerals, and modification of food consistency. Diets rich in protein and/or L-alanine and low in carbohydrates have shown positive results in PDJ-A. Supplement with 1.4 g of L-Alanine up to 04 times a day is indicated if the recommended protein content associated with 4% (500 ml) of branched-chain amino acids cannot be met. Results are optimized with training and physical activity. Body composition measurements include body mass index (kg/m 2 ) calculation, waist circumference and/or plicometry and Dual-energy X-ray absorptiometry (DXA).
Approaches to gastrointestinal problems include postural swallowing techniques, swallowing maneuvers to improve facial muscle coordination (supraglottic, Mendelsohn maneuver), environmental modifications, and oral sensory awareness techniques. The use of a feeding tube (nasal tube, gastrostomy or gastrojejunostomy tube) should also be considered.
swallowing
In PD patients with dysphagia, positive results have been obtained with a soft diet consisting of purees and similar preparations, and including the use of thickeners.
Percutaneous endoscopic gastrostomy (PEG) is a surgical endoscopic procedure that aims to provide extended food access for patients with an intact and functional gastrointestinal tract, but who are unable to maintain adequate oral energy intake 54 . PEG is indicated for PDJ-A patients with severe dysphagia, aspiration risk, weight loss (>10% in one year) and FVC < 40% 
anesthesia/surgery
The medical staff must carefully attend to a series of considerations when indicating surgery to patients with PD, because the increase risk of complications involving anesthesia 55 (B/C).
Patients with neuromuscular diseases due to metabolic causes may have a higher risk of adverse events to general anesthetics, especially the combination of halothane and succinylcholine 55 . The following guidelines are recommended for surgery procedures in PDJ-A:
• Conduct anesthetic procedures only when necessary;
• Consolidate all surgical procedures requiring anesthesia to reduce the risk of exposure to the anesthetic; • Avoid tracheal intubation and, if indicated, make sure it is performed by an experienced professional; • Conduct rigorous intraoperative supervision;
• Use inhalation agents in non-severe patients;
• Avoid depolarizing agents due to the risk of severe hyperkalemia; • Monitor circulating fluid volume; • Whenever possible, perform surgery in centers with professionals experienced with PD.
family history and genetic counseling PD is an autosomal recessive disease caused by pathogenic mutations in both alleles of the GAA gene 1, 7 . Parents of individuals with PD are healthy obligatory heterozygotes with a risk of PD recurrence in their future offspring of approximately 25%. Therefore, once an individual is diagnosed with PD, it is essential for parents to receive genetic counseling. The diagnosis of an individual with PD justifies the active search of the disease among his/ her siblings. Asymptomatic or mildly symptomatic cases are often identified due to the intrafamilial clinical variability observed between two siblings with PD. Laboratory screening and diagnostic methods are the same as for the index case (Table 4) .
Individuals with PDJ-A have benefited from ERT, with increased survival rates. As a result, some of them may have families once they reach reproductive age, especially those who are mildly symptomatic or diagnosed with late PD. An individual with PD can have an affected child if his/her partner is heterozygous for mutations in the gene that causes the disease. Pregnant women with PD require intensive supervision (see Pregnancy). The citation numbers and the references were modified, as shown below:
should be should be 
